Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer
- 218 Downloads
Evidence has accumulated that invasion and metastasis in solid tumors require the action of tumor-associated proteases, which promote the dissolution of the surrounding tumor matrix and the basement membranes. The serine protease urokinase-type plasminogen activator (uPA), which is elevated in solid tumors, appears to play a key role in these processes.
We used enzyme-linked immunoassays (ELISA) to test for uPA antigen and its inhibitor PAI-1 in tumor tissue extracts of 247 breast cancer patients who were enrolled in a prospective study. The relation of these data to known prognostic factors and to other variables such as DNA analysis and cathepsin D was studied. Disease-free and overall survival were analyzed according to Cox's proportional hazard model.
The major new finding is that breast cancer patients with either high uPA (>2.97 ng/mg protein) or high content of the uPA inhibitor PAI-1 (>2.18 ng/mg protein) in their primary tumors have an increased risk of relapse and death. Multivariate analyses revealed uPA to be an independent and strong prognostic factor. The impact of uPA is as high as that of the lymph node status. In node-negative patients the impact of uPA is closely followed by that of PAI-1. Since uPA and PAI-1 are independent prognostic factors, the node-negative patients could be subdivided further by combining these two variables. In this refined analysis, patients whose primary tumors have lower levels of both antigens evidently have a very low risk of relapse (93% disease-free survival at three years) in contrast to patients with high uPA and high PAI-1 (55% disease-free survival at three years).
The combination of uPA and PAI-1 in our group of patients with axillary node-negative breast cancer allows us to identify the 45 percent of patients having an increased risk of relapse. Consequently, more than half of the patients had less than a 10% probability of relapse and thus would possibly be candidates for being spared the necessity of adjuvant therapy.
Key wordsprotease inhibitor urokinase uPA PAI-1 cathepsin D prognosis breast cancer axillary node-negative patients
Unable to display preview. Download preview PDF.
- 3.Blasi F: Surface receptors for urokinase plasminogen activator. Fibrinolysis 2:73–84, 1988Google Scholar
- 8.Bachmann F: Thrombosis and haemostasis.In Verstraete M, Lijnen HR, Arnout J (eds). International Society on Thrombosis and Haemostasis, Leuven University Press, Leuven, 1987, pp 227–265Google Scholar
- 9.Kobayashi H, Schmitt M, Goretzki L, Chucholowski N, Calvete J, Kramer M, Günzler WA, Jänicke F, Graeff H: Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-uPA). J Biol Chem 266:5147–5152, 1990Google Scholar
- 11.Miles LA, Plow EF: Plasminogen receptors: Ubiquitous sites for cellular regulation of fibrinolysis. Fibrinolysis 2:61–71, 1988Google Scholar
- 12.Trygvasson K: Extracellular matrix and its enzymatic degradation in tumor invasion (A review).In Liotta LA (ed) Influence of Tumor Development on the Host. Kluwer Academic Publishers, Dordrecht, 1989, pp. 72–83Google Scholar
- 17.Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ: Urokinase plasminogen activator and prognosis in breast cancer. Lancet 335:108, 1990Google Scholar
- 18.Jänicke F, Schmitt M, Ulm K, Gössner W, Graeff H: Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet ii:1049, 1989Google Scholar
- 19.Jänicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, Gössner W, Graeff H: Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4:69–78, 1990Google Scholar
- 22.Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1–15 + 71–85, 1992Google Scholar
- 24.Schmitt M, Kanayama N, Henschen A, Hollrieder A, Hafter R, Gulba D, Jänicke F, Graeff H: Elastase released from human granulocytes stimulated with N-formyl-chemotactic peptide prevents activation of tumor cell prourokinase. FEBS Lett 255:85–88, 1989Google Scholar
- 25.Schmitt M, Jänicke F, Hafter R, Hollrieder A, Kanayama N, Gulba D, Graeff H: Tumor-associated fibrinolysis in human breast cancer: Detection and quantitation of the urokinase-type plasminogen activator (uPA) by ELISA and immunohistochemistry.In Matsuda M, Iwanaga S, Takada A, Henschen A (eds) Fibrinogen 4. Current Basic and Clinical Aspects. Elsevier, Amsterdam, 1990, pp 213–222Google Scholar
- 28.Cox DR: Regression models and life-tables. J R Stat Soc (B) 34:187–220, 1972Google Scholar
- 29.Hawkins DM: Testing a sequence of observations for a shift in location. J Am Stat Assoc 72:180–186, 1977Google Scholar
- 31.Breiman L, Friedman JH, Olsen RA, Stone CJ: Classification and Regression Trees. Wadsworth, Belmont, 1984Google Scholar
- 33.Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481, 1958Google Scholar
- 34.Peto R, Peto J: Asymptotically efficient rank invariant procedures. J Royal Stat Soc (A) 135:185–207, 1972Google Scholar
- 40.Spyratos F, Maudelonde T, Brouillet J-P, Brunet M, Defrenne A, Andrieu C, Hacene K, Desplaces A, Rouesse J, Rochefort H: Cathepsin D: An independent prognostic factor for metastasis of breast cancer. Lancet ii:1115–1118, 1989Google Scholar